Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study

Objectives: Lateral geniculate nucleus (LGN) volume is reduced after optic neuritis (ON) in neuromyelitis optica spectrum disorders (NMOSD). We aimed at a longitudinal assessment of LGN volume in NMOSD. Methods: Twenty-nine patients with aquaporin 4-IgG seropositive NMOSD (age: 47.8 ± 14.6 years (y)...

Full description

Bibliographic Details
Main Authors:	Athina Papadopoulou, Frederike C. Oertel, Claudia Chien, Joseph Kuchling, Hanna G. Zimmermann, Nadja Siebert, Seyedamirhosein Motamedi, Marcus D' Souza, Susanna Asseyer, Judith Bellmann-Strobl, Klemens Ruprecht, M. Mallar Chakravarty, Michael Scheel, Stefano Magon, Jens Wuerfel, Friedemann Paul, Alexander U. Brandt
Format:	Article
Language:	English
Published:	Elsevier 2021-01-01
Series:	NeuroImage: Clinical
Subjects:	Thalamus Neurodegeneration NMOSD Anterograde degeneration
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213158221000528

id	doaj-4d92d201ac8b4ad5a5a1cd5383b5c2d1
record_format	Article
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Athina Papadopoulou Frederike C. Oertel Claudia Chien Joseph Kuchling Hanna G. Zimmermann Nadja Siebert Seyedamirhosein Motamedi Marcus D' Souza Susanna Asseyer Judith Bellmann-Strobl Klemens Ruprecht M. Mallar Chakravarty Michael Scheel Stefano Magon Jens Wuerfel Friedemann Paul Alexander U. Brandt
spellingShingle	Athina Papadopoulou Frederike C. Oertel Claudia Chien Joseph Kuchling Hanna G. Zimmermann Nadja Siebert Seyedamirhosein Motamedi Marcus D' Souza Susanna Asseyer Judith Bellmann-Strobl Klemens Ruprecht M. Mallar Chakravarty Michael Scheel Stefano Magon Jens Wuerfel Friedemann Paul Alexander U. Brandt Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study NeuroImage: Clinical Thalamus Neurodegeneration NMOSD Anterograde degeneration
author_facet	Athina Papadopoulou Frederike C. Oertel Claudia Chien Joseph Kuchling Hanna G. Zimmermann Nadja Siebert Seyedamirhosein Motamedi Marcus D' Souza Susanna Asseyer Judith Bellmann-Strobl Klemens Ruprecht M. Mallar Chakravarty Michael Scheel Stefano Magon Jens Wuerfel Friedemann Paul Alexander U. Brandt
author_sort	Athina Papadopoulou
title	Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study
title_short	Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study
title_full	Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study
title_fullStr	Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study
title_full_unstemmed	Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study
title_sort	lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: a longitudinal study
publisher	Elsevier
series	NeuroImage: Clinical
issn	2213-1582
publishDate	2021-01-01
description	Objectives: Lateral geniculate nucleus (LGN) volume is reduced after optic neuritis (ON) in neuromyelitis optica spectrum disorders (NMOSD). We aimed at a longitudinal assessment of LGN volume in NMOSD. Methods: Twenty-nine patients with aquaporin 4-IgG seropositive NMOSD (age: 47.8 ± 14.6 years (y), female: n = 27, history of ON (NMO-ON): n = 17, median time since ON: 3[1.2–12.1]y) and 18 healthy controls (HC; age: 39.3 ± 15.8y; female: n = 13) were included. Median follow-up was 4.1[1.1–4.7]y for patients and 1.7[0.9–3.2]y for HC. LGN volume was measured using a multi-atlas-based approach of automated segmentation on 3 Tesla magnetic resonance images. Retinal optical coherence tomography and probabilistic tractography of the optic radiations (OR) were also performed. Results: At baseline, NMO-ON patients had lower LGN volumes (395.4 ± 48.9 mm3) than patients without ON (NMO-NON: 450.7 ± 55.6 mm3; p = 0.049) and HC (444.5 ± 61.5 mm3, p = 0.025). LGN volume was associated with retinal neuroaxonal loss and microstructural OR damage. Longitudinally, there was no change in LGN volumes in the absence of ON, neither in all patients (B = −0.6, SE = 1.4, p = 0.670), nor in NMO-ON (B = −0.8, SE = 1.6, p = 0.617) and NMO-NON (B = 1.7, SE = 3.5, p = 0.650). However, in four patients with new ON during follow-up, LGN volume was reduced at last visit (median time since ON: 2.6 [1.8–3.9] y) compared to the measurement before ON (352 ± 52.7 vs. 371.1 ± 55.9 mm3; t = −3.6, p = 0.036). Conclusion: Although LGN volume is reduced after ON in NMOSD, this volume loss is not progressive over longer follow-up or independent of ON. Thus, our findings -at least in this relatively small cohort- do not support occult neurodegeneration of the afferent visual pathway in NMOSD.
topic	Thalamus Neurodegeneration NMOSD Anterograde degeneration
url	http://www.sciencedirect.com/science/article/pii/S2213158221000528
work_keys_str_mv	AT athinapapadopoulou lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy AT frederikecoertel lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy AT claudiachien lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy AT josephkuchling lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy AT hannagzimmermann lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy AT nadjasiebert lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy AT seyedamirhoseinmotamedi lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy AT marcusdsouza lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy AT susannaasseyer lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy AT judithbellmannstrobl lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy AT klemensruprecht lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy AT mmallarchakravarty lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy AT michaelscheel lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy AT stefanomagon lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy AT jenswuerfel lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy AT friedemannpaul lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy AT alexanderubrandt lateralgeniculatenucleusvolumechangesafteropticneuritisinneuromyelitisopticaalongitudinalstudy
_version_	1721380479833210880
spelling	doaj-4d92d201ac8b4ad5a5a1cd5383b5c2d12021-06-13T04:37:50ZengElsevierNeuroImage: Clinical2213-15822021-01-0130102608Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal studyAthina Papadopoulou0Frederike C. Oertel1Claudia Chien2Joseph Kuchling3Hanna G. Zimmermann4Nadja Siebert5Seyedamirhosein Motamedi6Marcus D' Souza7Susanna Asseyer8Judith Bellmann-Strobl9Klemens Ruprecht10M. Mallar Chakravarty11Michael Scheel12Stefano Magon13Jens Wuerfel14Friedemann Paul15Alexander U. Brandt16Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Neurologic Clinic and Policlinic, Department of Medicine, Clinical Research and Biomedicine University Hospital Basel, University of Basel, Basel, SwitzerlandExperimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Neurology, University of California San Francisco, CA, USAExperimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyExperimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyExperimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyExperimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyExperimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyExperimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Neurologic Clinic and Policlinic, Department of Medicine, Clinical Research and Biomedicine University Hospital Basel, University of Basel, Basel, SwitzerlandExperimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyExperimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyDepartment of Neurology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyCerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Canada; McGill University, Department of Psychiatry and Department of Biomedical Engineering, Montreal, CanadaExperimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Neuroradiology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyNeurologic Clinic and Policlinic, Department of Medicine, Clinical Research and Biomedicine University Hospital Basel, University of Basel, Basel, Switzerland; Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, SwitzerlandMedical Image Analysis Center (MIAC AG) and Department for Biomedical Engineering, Basel, SwitzerlandExperimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Neurology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyExperimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Neurology, University of California Irvine, CA, USA; Corresponding author at: NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, Charitéplatz 1, DE-10117 Berlin, Germany.Objectives: Lateral geniculate nucleus (LGN) volume is reduced after optic neuritis (ON) in neuromyelitis optica spectrum disorders (NMOSD). We aimed at a longitudinal assessment of LGN volume in NMOSD. Methods: Twenty-nine patients with aquaporin 4-IgG seropositive NMOSD (age: 47.8 ± 14.6 years (y), female: n = 27, history of ON (NMO-ON): n = 17, median time since ON: 3[1.2–12.1]y) and 18 healthy controls (HC; age: 39.3 ± 15.8y; female: n = 13) were included. Median follow-up was 4.1[1.1–4.7]y for patients and 1.7[0.9–3.2]y for HC. LGN volume was measured using a multi-atlas-based approach of automated segmentation on 3 Tesla magnetic resonance images. Retinal optical coherence tomography and probabilistic tractography of the optic radiations (OR) were also performed. Results: At baseline, NMO-ON patients had lower LGN volumes (395.4 ± 48.9 mm3) than patients without ON (NMO-NON: 450.7 ± 55.6 mm3; p = 0.049) and HC (444.5 ± 61.5 mm3, p = 0.025). LGN volume was associated with retinal neuroaxonal loss and microstructural OR damage. Longitudinally, there was no change in LGN volumes in the absence of ON, neither in all patients (B = −0.6, SE = 1.4, p = 0.670), nor in NMO-ON (B = −0.8, SE = 1.6, p = 0.617) and NMO-NON (B = 1.7, SE = 3.5, p = 0.650). However, in four patients with new ON during follow-up, LGN volume was reduced at last visit (median time since ON: 2.6 [1.8–3.9] y) compared to the measurement before ON (352 ± 52.7 vs. 371.1 ± 55.9 mm3; t = −3.6, p = 0.036). Conclusion: Although LGN volume is reduced after ON in NMOSD, this volume loss is not progressive over longer follow-up or independent of ON. Thus, our findings -at least in this relatively small cohort- do not support occult neurodegeneration of the afferent visual pathway in NMOSD.http://www.sciencedirect.com/science/article/pii/S2213158221000528ThalamusNeurodegenerationNMOSDAnterograde degeneration

Lateral geniculate nucleus volume changes after optic neuritis in neuromyelitis optica: A longitudinal study

Similar Items